0001586939-14-000002.txt : 20140402 0001586939-14-000002.hdr.sgml : 20140402 20140402120038 ACCESSION NUMBER: 0001586939-14-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140402 DATE AS OF CHANGE: 20140402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Peter D CENTRAL INDEX KEY: 0001586939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 14736926 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2014-03-31 0 0001434316 FATE THERAPEUTICS INC FATE 0001586939 Flynn Peter D C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121 0 1 0 0 See remarks Common Stock 2014-03-31 4 S 0 2392 10.0821 D 8377 D Common Stock 2014-03-31 4 S 0 300 10.7733 D 8077 D Common Stock 2014-04-01 4 S 0 1346 9.0465 D 6731 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.65 to $10.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.66 to $11.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.92 to $9.1878, inclusive. Senior Vice President, Early Program Development /s/ Cindy R. Tahl, as Attorney-in-Fact 2014-04-01